Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster goes off patent in 2028.
Merck’s Subcutaneous Keytruda Meets Expectations in Phase III Read More »
The department hasn’t implemented some policies recommended by the watchdog, which could pose a risk to cybersecurity in the sector as attacks increase, according to the Government Accountability Office.
HHS facing challenges as lead agency for healthcare cybersecurity: GAO Read More »
Failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells investors that it’s evaluating its options for the program.
Neurogene Drops Batten Gene Therapy Program in Second Blow This Week Read More »
Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than Pfizer’s already established tafamidis.
ATTR-CM Approval for BridgeBio Could Trigger Tight Race with Pfizer Read More »
Las piedras hematita son mucho más que un adorno brillante. Desde tiempos antiguos, estas gemas han capturado la atención por su aspecto metálico y sus supuestas propiedades energéticas. Ideales para quienes buscan piezas únicas y llenas de significado, l …
Piedras hematita, el equilibrio perfecto entre belleza y energía Read More »
Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop in the biomarker after 12 weeks.
Lilly Plots Path for Cholesterol Pill After Strong Mid-Stage Showing Read More »
Incyte’s pipeline updates on Monday bring into question the value of its $750 million Escient acquisition in April 2024—and further erode confidence that the biotech can effectively mitigate the impacts of Jakafi’s loss of exclusivity in the coming years, according to analysts.
Incyte’s $750M Escient Bet Flops as Skin Disease Assets Stumble Read More »
Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for 2026—potentially posing a threat to Sarepta’s Elevidys.
Pocas personas pueden vivir hoy en día sin un dispositivo móvil o acceso a internet. La vida se ha hecho más fácil desde que llegó la digitalización y las transacciones online. Por supuesto que no todas son ventajas, los riesgos están presen …
La IGFBP3 es una molécula ampliamente estudiada tanto en procesos patológicos —como el cáncer—, como fisiológicos, y está implicada en la regulación de la proliferación, la diferenciación y la supervivencia celular. En un nuevo estu …
Identifican un mecanismo clave en el desarrollo pulmonar humano Read More »
